Soc. Generale Call 65 GILD 20.09..../ DE000SW1YW38 /
| 9/3/2024 9:37:37 AM | Chg.+0.02 | Bid4:55:42 PM | Ask4:55:42 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 1.21EUR | +1.68% | 1.38 Bid Size: 100,000 |
- Ask Size: - |
Gilead Sciences Inc | 65.00 USD | 9/20/2024 | Call |
GlobeNewswire
8/8
HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
8/8
Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates
GlobeNewswire
8/8
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results
GlobeNewswire
8/6
MacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results
GlobeNewswire
8/1
Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
GlobeNewswire
7/23
ACTG Presents Data Analysis at AIDS 2024 Showing Association between Elevated Risk of Cardiovascular...
GlobeNewswire
7/15
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inh...
GlobeNewswire
7/1
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment o...
GlobeNewswire
7/1
Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Offi...
GlobeNewswire
6/28
Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease
GlobeNewswire
6/26
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs
GlobeNewswire
6/26
Oruka Therapeutics Announces Key Additions to Leadership Team and Board of Directors
GlobeNewswire
6/18
Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation C...
GlobeNewswire
6/10
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus He...
